OncoSec Medical to Present Data at ESMO 2014 Congress
September 09 2014 - 6:02AM
Business Wire
OncoSec Medical Inc. (OTCQB: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, will present data
from ongoing clinical and pre-clinical studies at the European
Society for Medical Oncology (ESMO) 2014 Congress, to be held
September 26-30 in Madrid, Spain. OncoSec is proud to be presenting
an abstract titled, “Immune correlates of intratumoral IL-12
electroporation”, as part of a poster presentation taking place
12:45 PM - 1:45 PM CEST on Sunday, September 28th.
“The data we are presenting support the ability of intratumoral
electroporation of IL-12 to generate not just a local anti-tumor
response, but evidence of response in distant lesions,” said Robert
H. Pierce, M.D., Chief Medical Officer at OncoSec. “Additionally,
pharmacodynamic data from tumor biopsy samples obtained from
patients participating in our ongoing Phase 2 melanoma study are
consistent with preclinical data in the B16 melanoma mouse model,
where we demonstrated that IL-12 is turning on an
interferon-gamma-driven signaling cascade, culminating in the
accumulation of tumor infiltrating lymphocytes, or TILs, which have
been shown to correlate with response to anti-PD-1 therapies. Based
on this biology, we will be testing the hypothesis that
intratumoral electroporation with IL-12 will help convert PD-1
non-responders into responders.”
OncoSec’s President and CEO, Punit Dhillon, said, “It is our
distinct honor to present our latest findings before the
prestigious ESMO 2014 Congress. Events like ESMO 2014 enable
important iterative thinking in the evolving field of cancer
biology, clinical oncology and the related development of new
therapies, all of which continue to provide new options for
patients in the ongoing effort to provide new treatments for these
difficult cancers. We are confident that OncoSec is contributing to
this collective body of knowledge through our unique technology and
development path forward. Based on the data we are presenting here
at ESMO 2014, and the FDA’s recent accelerated approval of the
first PD-1 inhibitor pembrolizumab (Keytruda®, Merck), we are
excited to now have the opportunity to investigate clinically the
potential benefit of our proprietary intratumoral electroporation
therapy with IL-12 to treat patients who do not respond to
anti-PD-1 therapy.”
Abstract information is as follows:
Abstract #1620P: Immune correlates of intratumoral IL-12
electroporation. R. Pierce. Sunday, September 28, 12:45 PM –
1:45 PM CEST. Madrid, Spain
About ESMO 2014
ESMO is Europe’s leading medical oncology society, and is
dedicated to informing, educating, and supporting each individual
practitioner and researcher in the rapidly evolving medical
oncology landscape. The theme for ESMO 2014 is ‘Precision Medicine
in Cancer Care’. This year’s congress will feature presentations of
some of the latest research and trials including targeted therapies
and immunotherapeutic approaches, joint symposia with
representatives of all cancer specialties, and robust debates on
the clinical challenges of supplying genuinely personalized cancer
treatment. The event is designed to provide attendees and
participants with plentiful opportunities to make new contacts,
discuss new findings, learn from experts, and review presentations
– both online and at the Congress itself. For more information,
please visit:
http://www.esmo.org/Conferences/ESMO-2014-Congress
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing
its ImmunoPulse immunotherapy to treat solid tumors. OncoSec
Medical's core technology leverages a proprietary electroporation
platform to enhance the local delivery and uptake of DNA
IL-12 and other DNA-based immune-modulating agents. Clinical
studies of ImmunoPulse have demonstrated an acceptable safety
profile and preliminary evidence of anti-tumor activity in the
treatment of various skin cancers, as well as the potential to
initiate a systemic immune response without the systemic toxicities
associated with other treatments. OncoSec's clinical programs
currently include three Phase 2 trials targeting metastatic
melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma,
conducted in collaboration with several prominent academic medical
centers. As the company continues to evaluate ImmunoPulse in these
indications, it is also investigating additional indications and
combination therapeutic approaches. For more information, please
visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
Investor Relations:OncoSec Medical Inc.Veronica Vallejo,
855-662-6732CFOinvestors@oncosec.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024